[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek E, Alonso MA, Chen YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res; 2006 Dec 1;12(23):6937-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.
  • PURPOSE: To compare gene expression profiles of chromophobe renal cell carcinoma (RCC) and benign oncocytoma, aiming at identifying differentially expressed genes.
  • EXPERIMENTAL DESIGN: Nine cases each of chromophobe RCC and oncocytoma were analyzed by oligonucleotide microarray.
  • Candidate genes that showed consistent differential expression were validated by reverse transcription-PCR using 25 fresh-frozen and 15 formalin-fixed, paraffin-embedded tumor samples.
  • RESULTS: Unsupervised hierarchical clustering separated the chromophobe RCC and oncocytoma into two distinct groups.
  • By a combination of data analysis approaches, we identified 11 candidate genes showing consistent differential expression between chromophobe RCC and oncocytoma.
  • Five of these genes, AP1M2, MAL2, PROM2, PRSS8, and FLJ20171, were shown to effectively separate these two tumor groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues.
  • Immunohistochemical analysis revealed selective expression of MAL2 and claudin 8 in distal renal tubules, with MAL2 antibody showing differential expression between chromophobe RCC and oncocytoma.
  • Functional analyses suggest that genes encoding tight junction proteins and vesicular membrane trafficking proteins, normally expressed in distal nephrons, are retained in chromophobe RCC and lost or consistently down-regulated in oncocytoma, indicating that these two tumor types, believed to be both derived from distal tubules, are likely distinctive in their histogenesis.
  • CONCLUSIONS: We showed that chromophobe RCC and oncocytoma are distinguishable by mRNA expression profiles and a panel of gene products potentially useful as diagnostic markers were identified.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145811.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AP1M2 protein, human; 0 / Adaptor Protein Complex 1; 0 / Adaptor Protein Complex mu Subunits; 0 / FLJ20171 protein, human; 0 / MAL2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / PROM2 protein, human; 0 / Proteolipids; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Vesicular Transport Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / prostasin
  •  go-up   go-down


2. Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K: Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens); 2009 Oct-Dec;8(4):303-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
  • The patient was a 70-year-old man with a recurrent pituitary tumor.
  • Three surgeries were performed but the tumor recurred.
  • Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made.
  • The tumor was a macroadenoma partly immunopositive for LH.
  • After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug.
  • Following Temozolomide administration the MRI demonstrated significant tumor necrosis.
  • The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045804.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Tanaka K, Kumano Y, Kanomata N, Takeda M, Hara I, Fujisawa M, Kawabata G, Kamidono S: Oncocytic adrenocortical carcinoma. Urology; 2004 Aug;64(2):376-7
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adrenocortical carcinoma.
  • Oncocytic adrenocortical carcinoma is rare.
  • We describe an additional case of oncocytic adrenocortical carcinoma.
  • Computed tomography demonstrated a massive tumor in the right abdomen.
  • Histologic examination revealed an oncocytic adrenocortical carcinoma.
  • Five months postoperatively, multiple metastases had developed and were treated with surgical resection, chemotherapy, vascular embolization, and radiotherapy.
  • At last follow-up, the patient was alive with pulmonary and adrenal metastases and undergoing treatment with mitotane.
  • [MeSH-minor] Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Embolization, Therapeutic. Etoposide / administration & dosage. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Mitotane / therapeutic use. Nephrectomy. Ribs / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15302503.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 7
  •  go-up   go-down


Advertisement
4. Mete O, Asa SL: Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions. Endocr Pathol; 2009;20(3):182-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions.
  • The laparoscopic left adrenalectomy specimen revealed an adrenal cortical adenoma composed of varying proportions of oncocytic and clear cells, predominantly showing central oncocytic change.
  • Ultrastructural study revealed that the inclusions originated in degenerating mitochondria, explaining their association with the oncocytic phenotype of the tumor.
  • [MeSH-minor] Aged. Antihypertensive Agents / therapeutic use. Female. Humans. Hyperaldosteronism / etiology. Hypertension / drug therapy. Hypertension / etiology. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):301-6 [18688642.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):938-46 [16133362.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):229-35 [12227948.001]
  • [Cites] Hepatogastroenterology. 2008 May-Jun;55(84):900-2 [18705293.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1817-8 [15900303.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Rhinology. 2007 Mar;45(1):89-92 [17432078.001]
  • [Cites] Cancer. 1970 Dec;26(6):1300-10 [5483659.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):225-32 [14990587.001]
  • [Cites] Hum Pathol. 2009 Apr;40(4):478-83 [19144383.001]
  • [Cites] Arch Pathol Lab Med. 1983 Apr;107(4):178-82 [6299227.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Pathol Int. 1996 Apr;46(4):286-91 [8726853.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]
  • (PMID = 19462261.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 4964P6T9RB / Aldosterone
  •  go-up   go-down


5. Dasanu CA, Alexandrescu DT: Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma. South Med J; 2008 Feb;101(2):196-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma.
  • An elderly patient who presented with bilateral perinephric diffuse large B-cell lymphoma and concomitant oncocytoma of the same location is reported.
  • Because of the patient's other medical conditions, systemic chemotherapy was not deemed feasible.
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364624.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ambrosini-Spaltro A, Salvi F, Betts CM, Frezza GP, Piemontese A, Del Prete P, Baldoni C, Foschini MP, Viale G: Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. Virchows Arch; 2006 Apr;448(4):442-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.
  • The purpose of the study is to highlight oncocytic modifications in rectal adenocarcinomas and evaluate a possible correlation with preoperative radiochemotherapy (RCT).
  • Twenty-eight cases of advanced rectal carcinoma, treated preoperatively by 5-fluorouracil (200-225 mg/m(2)) and 44-46 Gy in 22-23 fractions, were studied.
  • In all cases oncocytic modifications were searched for on hematoxylin and eosin (H&E) and at immunohistochemistry using an antimitochondrial antibody.
  • In addition, in two cases, both pre- and post-RCT tissues were examined at electron microscopy.
  • In pre-RCT biopsies, oncocytic changes were difficult to find on H&E, while the antimitochondrial antibody strongly stained numerous neoplastic cells (mean 48.4%).
  • In post-RCT surgical specimens, oncocytic changes were detected in 24 out of 28 cases on H&E and the antimitochondrial antibody stained most of the residual neoplastic cells (mean 76.7%).
  • Ultrastructural examination revealed large and bizarre mitochondria inside tumor cells both in pre- and post-RCT tissues.
  • After preoperative RCT, residual neoplastic cells acquire a definite oncocytic phenotype.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Cytoplasm / ultrastructure. Female. Fluorouracil / therapeutic use. Humans. Male. Neoplasm, Residual / pathology. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1977 Aug;2(3):199-206 [589840.001]
  • [Cites] Histopathology. 2001 Nov;39(5):546-7 [11737320.001]
  • [Cites] Free Radic Biol Med. 1998 Mar 1;24(4):586-93 [9559871.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1826-38 [15774776.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):267-73 [9769131.001]
  • [Cites] Cancer Lett. 2004 Aug 20;212(1):105-11 [15246566.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] FASEB J. 1993 Feb 1;7(2):361-8 [8440412.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):665-74 [11395234.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):579-82 [12955503.001]
  • [Cites] Lab Invest. 1962 Nov;11:933-41 [13975331.001]
  • [Cites] Virchows Arch. 2005 Feb;446(2):127-35 [15602683.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):498-504 [11914629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):57-61 [7721640.001]
  • [Cites] Histopathology. 2004 Jul;45(1):91-3 [15228453.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):666-71 [15966178.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):215-23 [15043311.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2541-8 [10375100.001]
  • [Cites] Int J Colorectal Dis. 1997;12 (1):19-23 [9112145.001]
  • [Cites] Radiat Res. 1998 Nov;150(5):505-12 [9806591.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2612-24 [10594856.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):502-8 [12677146.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):613-21 [15695406.001]
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):305-15 [1636432.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):126-34 [10452578.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6641-6 [10597269.001]
  • [Cites] Neuropathology. 2002 Mar;22(1):19-25 [12030411.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):312-9 [10733111.001]
  • [Cites] Pathologe. 2003 Feb;24(1):61-5 [12601479.001]
  • [Cites] J Mol Endocrinol. 2001 Feb;26(1):67-77 [11174855.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):922-30 [9255255.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3517-25 [15908662.001]
  • [Cites] J Pathol. 2004 Oct;204(2):183-92 [15378567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • (PMID = 16365727.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Cimmino A, Giangaspero F, Pennella A, Serio G, De Tomasi A, Colamaria A, Ricco R: [Oncocytic meningioma. Case report]. Pathologica; 2000 Apr;92(2):82-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncocytic meningioma. Case report].
  • Among the histological variants of meningiomas the oncocytic subtype is rarely observed.
  • Up-today, only six cases of oncocytic meningioma are described.
  • We describe a case of oncocytic meningioma in a 78-years-old woman.
  • The patient had a history of breast cancer diagnosed 9 years before the brain biopsy; bilateral mastectomy and adjuvant chemotherapy was performed.
  • Oncocytic differentiation was demonstrated by conventional histology and immunohistochemistry.
  • The rarity of oncocytic meningiomas is underlined with only six cases described in the world literature.
  • The immunophenotypic profile and the differential diagnosis of the neoplasm is discussed and the concept of oncocytic meningioma as a distinct entity of tumour is emphasized.
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Brain Edema / etiology. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Breast Neoplasms. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / secondary. Carcinoma, Medullary. Diagnosis, Differential. Female. Humans. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10838873.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Hogan T, Jing Jie Yu, Williams HJ, Altaha R, Xiaobing Liang, Qi He: Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract; 2009 Jun;15(2):111-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
  • OBJECTIVE: To highlight the molecular findings and clinical response of a patient with rapidly progressing, focally anaplastic, oncocytic thyroid carcinoma (OTC) treated with erlotinib.Case Summary.
  • A 69-year-old woman with recurrent, focally anaplastic OTC was given a therapeutic trial of erlotinib, a small molecule inhibitor of epidermal growth factor receptor (EGFR).
  • Formalin-fixed, paraffin-embedded portions of the tumor were analyzed for EGFR expression, and tumor genomic DNA was amplified by polymerase chain reaction (PCR) and subjected to EGFR mutation analysis.Discussion.
  • The tumor was focally positive for EGFR by immunostaining and two point mutations were identified, one on exon 18 and one on exon 20 in the tyrosine kinase (TK) domain.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / pathology. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Erlotinib Hydrochloride. Female. Humans. Point Mutation. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276143.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


9. Pan CC, Chen PC, Ho DM: The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology; 2004 Nov;45(5):452-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
  • AIMS: To demonstrate the diagnostic utility of MOC31, BerEP4, renal cell carcinoma marker (RCC Ma) and CD10 in the classification of RCC and renal oncocytoma, based upon a comprehensive immunohistochemical analysis.
  • MOC31 and BerEP4 chiefly labelled distal tubules of normal kidney while RCC Ma and CD10 labelled the proximal tubules.
  • The non-reactivity for both MOC31 and CD10 is helpful in distinguishing renal oncocytoma from RCC.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases. Neprilysin
  • [MeSH-minor] Antigens, Neoplasm. Biomarkers. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500648.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


10. Kuroda N, Guo L, Toi M, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Shuin T, Enzan H: Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol; 2001 Dec;9(4):315-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
  • In a normal kidney, paxillin was predominantly expressed in the cytoplasm of distal tubules, loops of Henle, collecting ducts, and vascular smooth muscle cells.
  • In all of the chromophobe RCCs and oncocytomas, strong expression of paxillin was observed in the tumor cytoplasm.
  • An immunoblot analysis confirmed the presence of paxillin in healthy kidney, chromophobe RCC, and oncocytoma.
  • These data suggest that paxillin possibly plays a role in signal transductions as a focal adhesion intervening between tumor cells and the extracellular matrix in renal tumors with collecting duct phenotypes such as chromophobe RCCs and oncocytomas, but not in conventional RCCs.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11759057.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / PXN protein, human; 0 / Paxillin; 0 / Phosphoproteins
  •  go-up   go-down


11. Zhou CX, Shi DY, Ma DQ, Zhang JG, Yu GY, Gao Y: Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases. Oral Oncol; 2010 Oct;46(10):773-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases.
  • Oncocytic carcinoma (OC) of salivary gland origin is an extremely rare proliferation of malignant oncocytes with adenocarcinomatous architectural phenotypes, including infiltrative qualities.
  • To help clarify the clinicopathologic and prognostic features of this tumor group, herein, we report 12 OC cases arising from the salivary glands, together with follow-up data and immunohistochemical observations.
  • The tumors were unencapsulated and often invaded into the nearby gland, lymphatic tissues and nerves.
  • In summary, OC of salivary gland origin is a high-grade tumor, often with local recurrence, regional or distant metastasis, diagnosis of which based on a combination of clinical and histopathological features.
  • Complete surgical excision is the treatment of choice while the role of radiotherapy or chemotherapy is controversial, and careful follow-up is necessary.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitochondria / ultrastructure. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20843731.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Giaslakiotis K, Androulaki A, Panagoulias G, Kyrtsonis MC, Lazaris AC, Kanakis DN, Patsouris ES: T cell lymphoblastic lymphoma in parotidectomy for Warthin's tumor: case report and review of the literature. Int J Hematol; 2009 Apr;89(3):359-64
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell lymphoblastic lymphoma in parotidectomy for Warthin's tumor: case report and review of the literature.
  • Lymphomas associated with Warthin's tumor (WT) are extremely uncommon and the majorities are of B cell type.
  • The parotidectomy specimen showed a WT with extensive replacement of the lymphoid stroma by T-LBL, but preservation of the oncocytic epithelium.
  • The patient received combination chemotherapy treatment but responded poorly, and died three months after diagnosis.
  • The present study indicates that the lymphoid stroma in WT belongs to the systemic lymphoid tissue and can be involved in disseminated lymphoma.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):264-9, 272-3 [8486105.001]
  • [Cites] Histopathology. 2005 Aug;47(2):221-2 [16045788.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2948-50 [7139585.001]
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):113-9 [10631864.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):212-5 [2184550.001]
  • [Cites] Histopathology. 1993 Mar;22(3):280-1 [8495960.001]
  • [Cites] Tohoku J Exp Med. 2007 Jun;212(2):199-205 [17548964.001]
  • [Cites] Hum Pathol. 1985 Apr;16(4):424-7 [3980011.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:307-24 [583554.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):974-7 [2394439.001]
  • [Cites] J Clin Pathol. 2005 Mar;58(3):331-3 [15735173.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Ear Nose Throat J. 1979 Aug;58(8):345-50 [583035.001]
  • [Cites] J Pathol. 1985 Jul;146(3):167-77 [3928854.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):341-4 [2538052.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):491-6 [3082065.001]
  • [Cites] Pathol Res Pract. 1986 Oct;181(5):615-20 [3786253.001]
  • (PMID = 19294485.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 19
  •  go-up   go-down


13. Okoń K: Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol; 2008;59(3):129-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the fifties, the incidence of renal cancers has been increasing, but at the some time the prognosis has been improving.
  • In particular, in the last years, several new treatment modalities have been introduced, relying on the understanding of renal cancer biology.
  • There are several renal tumor types differing in morphology, molecular genetics and biology.
  • At least two types of papillary carcinomas exist, which have different morphology and prognosis.
  • The molecular biology of chromophobe carcinoma and oncocytoma is poorly understood.
  • Some renal tumors have been described or recognized only relatively recently; these newer entities include multilocular cystic clear cell carcinoma, spindle cell papillary mucinous carcinoma, tubulocystic carcinoma, renal epithelial and stromal tumor, epithelioid and oncocytic angiomyolipoma.
  • Besides histological typing, the prognostic factors include tumor stage, grade and several immunohistochemical and molecular markers that are currently under elaboration.
  • The improved prognosis in renal cancer depends on earlier detection, but also on refinement of therapeutic methods.
  • Renal carcinoma is notorious for its low sensitivity to chemotherapy and radiotherapy.
  • For several years, immunological treatment with IL-2 and INF-alpha was the only adjuvant therapy method.
  • However, recently several new drugs have been introduced; they act on tyrosine-kinase receptors, VEGF, c-Met or mTOR pathway.
  • With this progress, perfect understanding of renal tumor biology and exact histological diagnosis have become of prime practical importance.


14. Matyja G, Dziekan T, Dobrzycki W: [Rare neck tumors: diagnosis and treatment]. Otolaryngol Pol; 2000;54 Suppl 31:87-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neck tumors: diagnosis and treatment].
  • Among them were: paraganglioma--3 cases, neurilemmoma--3 cases, actinomycosis--2 cases and 1 case of plasmocytoma, ganglioneuroma, oncocytoma, lipoma, toxoplasmosis and cystic tumour of salivary gland origin.
  • Beside surgery antibiotics, chemotherapy and RTG therapy were applied, depending on the kind of the tumour.
  • Satisfactory results were obtained (12/14 patients are alive, 1 after removal of oncocytoma died due to cardio-vascular cause).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974852.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


15. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol; 2009 May;181(5):2305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
  • PURPOSE: The similar appearance of renal tumor histological subtypes can complicate differential diagnoses.
  • This problem is most notable for the chromophobe subtype of renal cell carcinoma, which can be histologically indistinguishable from oncocytoma with investigational molecular markers failing to provide reliable differentiation.
  • KAI1 is a metastasis suppressor gene whose expression correlates inversely with the metastatic potential of most solid tumor cancer types.
  • We tested the hypothesis that KAI1 is differentially expressed among renal tumor histological subtypes.
  • MATERIALS AND METHODS: Immunohistochemical staining for KAI1 protein was performed in 152 nephrectomy specimens, including 48 clear cell, 35 papillary and 31 chromophobe renal cell carcinoma samples, 28 oncocytomas and 10 tumor-free kidneys.
  • KAI1 mRNA levels were compared by quantitative reverse transcriptase-polymerase chain reaction in an additional 22 chromophobe renal cell carcinoma and oncocytoma samples.
  • RESULTS: In all 10 tumor-free kidneys KAI1 protein was detected exclusively in distal tubule cell membranes.
  • Of the tumor specimens KAI1 protein was absent in all papillary renal cell carcinoma specimens.
  • The diagnostic accuracy of KAI1 immunostaining for discerning chromophobe renal cell carcinoma from oncocytoma was 90% with similar results observed at the RNA level.
  • CONCLUSIONS: KAI1 is an accurate biomarker for chromophobe renal cell carcinoma that may aid in the diagnostic differentiation of chromophobe renal cell carcinoma from oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Extracellular Matrix Proteins / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biopsy, Needle. Case-Control Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Nephrectomy. Prognosis. Reference Values. Risk Assessment. Sampling Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303095.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / KAL1 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


16. Seveso M, Taverna G, Giusti G, Benetti A, Piccinelli A, Graziotti P: Nephron sparing surgery of parenchymal kidney tumours in solitary kidney. Arch Ital Urol Androl; 2007 Mar;79(1):12-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The aim of this study is to assess the therapeutic efficacy of nephron sparing surgery (NSS) in our experience applied to patients with either bilateral renal cancer or patients with cancer in a solitary functioning kidney, from an oncological viewpoint as well as renal function.
  • Final histology showed 17 patients with clear cell renal carcinoma, six papillary cell carcinomas, one chromophobe carcinoma, one oncocytoma and two angiomyolipomas.
  • Two patients present secondary tumours (lung and liver), whereas one patient is being treated with chemotherapy for colon cancer Twenty-two patients are disease-free.
  • None of the 10 patients discharged with creatinine levels >2 mg/dL, were submitted to dialytic therapy during follow-up.
  • None of the patients discharged with normal renal function developed kidney failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484397.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, Haitel A: CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest; 2009 Apr;39(4):304-10
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a variety of malignant diseases, molecular targeting represents a therapeutic option, whereby, when compared with chemotherapy, fewer side effects are thought to be expected.
  • Especially in renal cell cancer (RCC), tyrosine kinase-inhibitors have been established as useful and highly effective therapy.
  • However, tyrosine kinase-inhibitors currently approved for RCC treatment lack single molecule specificity and bear a variety of side effects of the gastro-intestinal tract, skin, heart and haematopoietic system.
  • Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer.
  • MATERIAL AND METHODS: Paraffin-embedded RCCs from a well characterized tissue bank were immunohistochemically quantified for embryonic transmembrane antigen CD98hc (SLC3A2) expression and semi-quantitative analyses were correlated with subtype or grade of differentiation.
  • RESULTS: We found increased CD98hc expression in different types of malign RCCs, among them clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC, but lack of expression in the benign renal oncocytoma.
  • Furthermore, the more malignant type II pRCC significantly higher expressed CD98hc than the less malignant and more differentiated type I pRCC (type II 83.34%, type I 4.76% CD98hc positive, P < 0.00001; n = 51).
  • The established marker for type I pRCC, Cytokreatin 7, showed 95.24% expression in type I and 26.67% expression in type II pRCC (P < 0.00001, n = 51).
  • In pRCCs, CD98hc might represent a novel and reliable marker for type II pRCC.
  • [MeSH-major] Antigens, CD98 Heavy Chain / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292886.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98 Heavy Chain; 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this report is to describe 3 cases of salivary gland tumors with intracranial extension associated to an extracerebral mass lesion, and to discuss the frequence, pathology and treatment of these very rare localizations.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • The location of the intradural extra-axial tumor was the middle fossa and temporal region in 2 cases and the cerebellopontine angle in 1.
  • Surgical treatment consisted in the seemingly complete removal of 2 tumors with middle fossa localization and partial removal of the cerebellopontine angle lesion.
  • Radiotherapy was administered in all 3 cases and chemotherapy in 2.
  • RESULTS: 1 patient is alive and free of recurrence 32 months after removal of the intracranial tumor; 2 other patients died 28 months and 12 months postoperatively.
  • [MeSH-minor] Adult. Aged. Brain / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Toma V, Zuber C, Sata T, Komminoth P, Hailemariam S, Eble JN, Heitz PU, Roth J: Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms. Hum Pathol; 2000 Jun;31(6):647-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In developing kidney, the TF was restricted to the loop of Henle, distal tubules, and peripheral collecting ducts, whereas its sialylated form was detectable in all epithelial differentiations derived from the 2 embryonic anlagen, the metanephrogenic blastema being unreactive.
  • Analysis of a spectrum of renal neoplasms failed to detect the TF, with the exception of occasional staining of tubules in nephroblastoma.
  • Moreover, the sialylated TF was only detectable in oncocytoma, chromophobe renal cell carcinoma, cystic nephroma, nephroblastoma, and nephroblastomatosis complex and occasionally in type 1 papillary renal cell carcinoma.
  • However, the TF does not seem to represent a tumor-associated glycotope in human kidney, nor does it appear to be of value in diagnosis and immunotherapy of renal neoplasms.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Kidney / immunology. Kidney Neoplasms / immunology. Plant Lectins
  • [MeSH-minor] Adult. Antibodies, Monoclonal. Coloring Agents. Gestational Age. Humans. Immunohistochemistry. Lectins. N-Acetylneuraminic Acid / analysis. Ribosome Inactivating Proteins. Wilms Tumor / immunology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10872656.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Coloring Agents; 0 / Lectins; 0 / Plant Lectins; 0 / amaranthin protein, Amaranthus; 3554-90-3 / Thomsen-Friedenreich antigen; EC 3.2.2.22 / Ribosome Inactivating Proteins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


20. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery for unilateral primary renal tumor in children.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.
  • [MeSH-minor] Child. Child, Preschool. Eligibility Determination. Female. Humans. Infant. Infant, Newborn. Life Expectancy. Male. Neoplasm Staging. Postoperative Complications. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, Arganini L, Taddei A, Ammannati F, Mennonna P, Taddei GL: Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):187-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry.
  • Experimental data suggest a possible therapeutic use of the COX-inhibitors nonsteroidal antiinflammatory drugs (NSAIDs).
  • NSAIDs can block tumor growth through many mechanisms, especially through antiangiogenic and proapoptotic effects.
  • Moreover, NSAIDs can also improve the efficacy of radiotherapy, chemotherapy, and hormonal therapy.
  • This study reviews the COX-2 expression as evaluated through immunohistochemistry and real time polymerase chain reaction (RT-PCR) in 23 meningiomas [14 World Health Organization (WHO) grade I; 5 WHO grade II; 3 WHO grade III; 1 oncocytic meningioma].
  • The association between tumor grade and immunohistochemical or RT-PCR COX-2 expression was not significant (P=0.427 and P=0.251, respectively).
  • In conclusion, even if further studies on larger series are necessary, the common COX-2 overexpression in meningiomas may suggest considering the COX-2 inhibitors, alone or in combination with radiotherapy, a potential area of therapeutic intervention in some selected meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525632.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


22. Fernández CA, Puig-Domingo M, Lomeña F, Estorch M, Camacho Martí V, Bittini AL, Marazuela M, Santamaría J, Castro J, Martínez de Icaya P, Moraga I, Martín T, Megía A, Porta M, Mauricio D, Halperin I: Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest; 2009 Mar;32(3):228-33
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.
  • BACKGROUND: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid neoplasia that have lost radioiodine (131I) uptake with heterogeneous results.
  • AIM: Retrospective analysis of the recovery rate of 131I uptake after RA treatment in patients from 11 Spanish hospitals.
  • METHODS: Twenty-seven patients (14 men, 13 women) with papillary [21], follicular [4], and oncocytic [2] thyroid cancer initially treated with total thyroidectomy plus 131I, and with 131I negative metastatic disease, were given 13-cis RA (0.66-1.5 mg/kg for 5-12 weeks) followed by a therapeutic 131I dose (3700-7400 MBq); 3 months later thyroglobulin levels and computed tomography imaging were performed.
  • RESULTS: In 9 out 27 cases (33%) (8 papillary, 1 follicular) optimal positive 131I scan was observed after RA treatment; in the remaining 18, 10 had a suboptimal uptake (7 papillary, 2 follicular, 1 oncocytic) and in the rest there was no 131I uptake recovery (6 papillary, 1 follicular, 1 oncocytic).
  • In 17 positive responses to RA (either optimal or suboptimal) in which image follow-up was available, decrease or stabilization of metastatic growth was observed in 7, while tumor mass increased at short term in the remaining 10.
  • CONCLUSION: Quite a high rate of 131I uptake recovery after RA treatment may be obtained in advanced differentiated thyroid cancer, but the potential modification of the natural course of the disease is uncertain.
  • A better biological characterization of these tumors allowing the identification of potential responders to RA may improve the outcome of RA coadjuvant therapy.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnostic imaging. Carcinoma, Papillary, Follicular / drug therapy. Cell Differentiation / drug effects. Iodine Radioisotopes / therapeutic use. Isotretinoin / therapeutic use. Thyroid Neoplasms / diagnostic imaging. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radionuclide Imaging. Recovery of Function / drug effects. Recovery of Function / radiation effects. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2002 Jul;3(7):407-14 [12142170.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1903-6 [9829580.001]
  • [Cites] Thyroid. 2000 May;10(5):393-406 [10884186.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):775-82 [12029551.001]
  • [Cites] Leukemia. 1998 Sep;12 Suppl 1:S37-40 [9777894.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:16-9 [8980993.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):257-69 [16601293.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]
  • [Cites] Endocr Pract. 2000 Nov-Dec;6(6):469-76 [11155222.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):272-80 [14715861.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):395-402 [12656659.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2406-12 [15944425.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1831-8 [16983703.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2493-6 [9661633.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Nov 26;240(3):832-8 [9398654.001]
  • [Cites] World J Surg. 1998 Jun;22(6):569-74 [9597930.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):525-31 [16556714.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Thyroid. 2006 Oct;16(10):1025-31 [17042689.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):334-9 [15233552.001]
  • [Cites] J Nucl Med. 1996 Apr;37(4):598-605 [8691248.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1871-6 [9652685.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):569-74 [15630851.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):368-76 [9579574.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • (PMID = 19542739.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EH28UP18IF / Isotretinoin
  •  go-up   go-down






Advertisement